Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation.

Kentaro Hayashida, Thierry Lefèvre

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.

Original languageEnglish
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Volume8 Suppl Q
Publication statusPublished - 2012 Sep
Externally publishedYes

Fingerprint

Aortic Valve Insufficiency
Transcatheter Aortic Valve Replacement
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{875638cf3a3f4fccac7ec6484749a90f,
title = "Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation.",
abstract = "Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.",
author = "Kentaro Hayashida and Thierry Lef{\`e}vre",
year = "2012",
month = "9",
language = "English",
volume = "8 Suppl Q",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",

}

TY - JOUR

T1 - Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation.

AU - Hayashida, Kentaro

AU - Lefèvre, Thierry

PY - 2012/9

Y1 - 2012/9

N2 - Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.

AB - Significant aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been shown to be associated with worse mid-term outcome. The two-year follow-up results of the PARTNER US trial showed that not only ≥3/4 AR grade, but also grade 2 had a significant impact on mortality. Thus, prevention and treatment of significant AR after TAVI is of great importance. Usually, AR after TAVI consists mostly of paravalvular leak and significant central AR is uncommon. Here we describe measures to decrease the risk of AR after TAVI which are currently available.

UR - http://www.scopus.com/inward/record.url?scp=84894368966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894368966&partnerID=8YFLogxK

M3 - Article

VL - 8 Suppl Q

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

ER -